{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:38Z","timestamp":1790874938034,"version":"4.1.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/jcp.0b013e31828ea95c","type":"journal-article","created":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T14:15:49Z","timestamp":1366467349000},"page":"398-404","source":"Crossref","is-referenced-by-count":92,"title":["Optimal Extent of Dopamine D2 Receptor Occupancy by Antipsychotics for Treatment of Dopamine Supersensitivity Psychosis and Late-Onset Psychosis"],"prefix":"10.1097","volume":"33","author":[{"given":"Masaomi","family":"Iyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Tadokoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Kanahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomihisa","family":"Niitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"5","key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia.","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med"},{"key":"R2-18-20210128","first-page":"135","article-title":"Pharmacotherapy for treatment-resistant schizophrenia.","volume":"7","author":"McIlwain","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R3-18-20210128","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/ajp.138.4.460","article-title":"Dopamine receptors, neuroleptics, and schizophrenia.","volume":"138","author":"Snyder","year":"1981","journal-title":"Am J Psychiatry"},{"key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neurolepticdopamine receptors.","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"issue":"1","key":"R5-18-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"Schizophrenia Patient Outcomes Research Team (PORT): the 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"issue":"9","key":"R6-18-20210128","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/01.mlr.0000215806.11805.6c","article-title":"Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences.","volume":"44","author":"Dickey","year":"2006","journal-title":"Med Care"},{"issue":"4","key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2753.2008.01084.x","article-title":"Explicit versus implicit review to explore combination antipsychotic prescribing.","volume":"15","author":"Wheeler","year":"2009","journal-title":"J Eval Clin Pract"},{"issue":"3","key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-199834030-00005","article-title":"The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.","volume":"34","author":"Ulrich","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"22","key":"R10-18-20210128","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.2174\/138161209788957528","article-title":"Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.","volume":"15","author":"Howes","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"3","key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JGP.0b013e318198776d","article-title":"Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.","volume":"17","author":"Uchida","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"R12-18-20210128","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eurpsy.2009.03.001","article-title":"Deficit schizophrenia: an overview of clinical, biological and treatment aspects.","volume":"24","author":"Galderisi","year":"2009","journal-title":"Eur Psychiatry"},{"key":"R13-18-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes.","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother Psychosom"},{"issue":"2","key":"R14-18-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine d2(high) receptors.","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"R15-18-20210128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study.","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0893-133X(87)90004-2","article-title":"Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimers, Parkinsons, and Huntingtons diseases.","volume":"1","author":"Seeman","year":"1987","journal-title":"Neuropsychopharmacology"},{"issue":"25","key":"R17-18-20210128","doi-asserted-by":"crossref","first-page":"L443","DOI":"10.1016\/0024-3205(95)00218-U","article-title":"Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats.","volume":"56","author":"Sasaki","year":"1995","journal-title":"Life Sci"},{"issue":"1-3","key":"R18-18-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0014-2999(95)00278-S","article-title":"Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol.","volume":"282","author":"Sasaki","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"R19-18-20210128","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/schbul\/sbr006","article-title":"Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.","volume":"38","author":"Tadokoro","year":"2012","journal-title":"Schizophr Bull"},{"issue":"S9","key":"R20-18-20210128","first-page":"25","article-title":"Pathophysiology of antipsychotic drug-induced movement disorders.","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"4681","key":"R22-18-20210128","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1126\/science.6334363","article-title":"Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain.","volume":"226","author":"Wong","year":"1984","journal-title":"Science"},{"issue":"3","key":"R23-18-20210128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0278-5846(93)90075-4","article-title":"The detection of age-related decrease of dopamine D1, D2 and serotonin 5-HT2 receptors in living human brain.","volume":"17","author":"Iyo","year":"1993","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"R24-18-20210128","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1017\/S1461145707008358","article-title":"Age-related diurnal effect on D2 receptor binding: a preliminary PET study.","volume":"11","author":"Cervenka","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"R25-18-20210128","first-page":"595","article-title":"D2-dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture.","volume":"27","author":"Weiss","year":"1985","journal-title":"Mol Pharmacol"},{"issue":"4","key":"R26-18-20210128","first-page":"560","article-title":"Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum.","volume":"37","author":"Enz","year":"1990","journal-title":"Mol Pharmacol"},{"issue":"3","key":"R27-18-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine d2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis.","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R28-18-20210128","first-page":"95","article-title":"Neurolepticdopamine receptors: elevation and reversal.","volume":"24","author":"List","year":"1980","journal-title":"Adv Biochem Psychopharmacol"},{"issue":"1","key":"R29-18-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.","volume":"45","author":"Farde","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"R30-18-20210128","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0006-3223(90)90611-5","article-title":"D2 receptor occupancy and plasma concentration of antipsychotics.","volume":"28","author":"Iyo","year":"1990","journal-title":"Biol Psychiatry"},{"key":"R31-18-20210128","first-page":"849","article-title":"High neuroleptic plasma levels in patients manifesting supersensitivity psychosis.","volume":"17","author":"Chouinard","year":"1982","journal-title":"Biol Psychiatry"},{"issue":"6","key":"R32-18-20210128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14740338.5.6.759","article-title":"Drug-induced parkinsonism.","volume":"5","author":"Mena","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"S2","key":"R33-18-20210128","first-page":"5","article-title":"Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients.","volume":"65","author":"Alexopoulos","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"R34-18-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action.","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"R35-18-20210128","first-page":"337","article-title":"Treatment of neuroleptic-induced supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases.","volume":"26","author":"Chouinard","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"R36-18-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-9964(91)90050-2","article-title":"Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.","volume":"5","author":"Chouinard","year":"1991","journal-title":"Schizophr Res"},{"issue":"6","key":"R38-18-20210128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0269881109359097","article-title":"A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis.","volume":"25","author":"Fallon","year":"2011","journal-title":"J Psychopharmacol"},{"key":"R39-18-20210128","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1097\/00004714-198808001-00005","article-title":"A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.","volume":"8","author":"Chouinard","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"R40-18-20210128","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpsyc.1991.01810320063009","article-title":"Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose.","volume":"48","author":"McEvoy","year":"1991","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"R41-18-20210128","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/0269881109106306","article-title":"Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia.","volume":"24","author":"Tenback","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R42-18-20210128","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/15622970802481895","article-title":"Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.","volume":"10","author":"Li","year":"2009","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"R45-18-20210128","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/JCP.0b013e318222353a","article-title":"Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with 11Craclopride.","volume":"31","author":"Kim","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"R46-18-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-003-1648-y","article-title":"Neuroleptic dysphoria: towards a new synthesis.","volume":"171","author":"Voruganti","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"R47-18-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1358\/dot.2007.43.4.1067342","article-title":"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.","volume":"43","author":"Owen","year":"2007","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"R48-18-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2003.11.001","article-title":"Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.","volume":"70","author":"Eerdekens","year":"2004","journal-title":"Schizophr Res"},{"key":"R49-18-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.schres.2013.01.008","article-title":"Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis.","volume":"145","author":"Kimura","year":"2013","journal-title":"Schizophr Res"},{"key":"R50-18-20210128","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1037\/1064-1297.15.6.569","article-title":"Aripiprazole: effectiveness and safety under naturalistic conditions.","volume":"15","author":"Di Lorenzo","year":"2007","journal-title":"Exp Clin Psychopharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31828ea95c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:01:21Z","timestamp":1620957681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201306000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31828ea95c","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}